Prostate specific membrane antigen (PSMA) is often overexpressed in men with advanced prostate cancer, this as-well as its specificity to the prostate region makes it a good therapeutic target for the treatment of advanced prostate cancer. 177Lu-PSMA-617 is a PSMA-targeted radionuclide therapy (PSMA-TRT), it consists of two components, the monoclonal antibody PSMA-617, which targets cancer cells, fused to the radioactive beta emitter lutetium-177 (177Lu), which kills cancer cells. Karim Fizazi, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses the design and results of the VISION trial (NCT03511664): a Phase III trial investigating the efficacy of best standard of care (BSOC) and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). Both primary endpoints were met; overall survival (OS) was 40% greater and progression-free survival (PFS) was 5 months greater in the treatment group. These results may facilitate the approval of 177Lu-PSMA-617 to treat mCRPC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.